J Diabetes Metab Disord . Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

[tetano]

J Diabetes Metab Disord


. 2021 Jun 26;1-6.
doi: 10.1007/s40200-021-00833-z. Online ahead of print.
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands


Rick I Meijer ¹ , Trynke Hoekstra ² , Niels C Gritters van den Oever ³ , Suat Simsek ^{4 5} , Joop P van den Bergh ⁶ , Renée A Douma ⁷ , Auke C Reidinga ⁸ , Hazra S Moeniralam ⁹ , Tom Dormans ¹⁰ , Amsterdam UMC COVID-19 biobank study group; Mark M Smits ^{5 11}



Affiliations

• PMID: 34222054
• PMCID: PMC8233181
• DOI: 10.1007/s40200-021-00833-z

Abstract

Purpose: Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study.
Methods: We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users.
Results: No differences were found in the primary outcome mortality (matched-analysis = odds-ratio: 0,94 [95% confidence interval: 0,69 - 1,28], p-value: 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1: users of metformin and sulphonylurea; subgroup 2: users of any insulin combination), allowing to correct for diabetes severity, did not yield different results.
Conclusions: We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.

Keywords: COVID-19; DPP-4 inhibitors; Mortality; Type 2 diabetes.